Skip to main content
OpenTrials
Completed

NCT Number: NCT01688934

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Genova Clinical Research, Inc., Tucson, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Subjects with moderate pain due to OA of the knee as their primary pain condition.
  • Subjects with diagnostic criteria for primary pain condition (American college of Rheumatology [ACR] clinical and radiographic criteria):
  • At least 1 of the following in addition to knee pain: age >50, stiffness <30 min, crepitus on active motion, and
  • Kellgren-Lawrence (K-L) grade ≥ 2 radiographic evidence within the past 2 years.

Key Exclusion Criteria:

  • Subjects with chronic pain conditions other than OA of the knee as their predominant pain condition, including gout, pseudo gout, psoriatic arthritis, active Lyme disease, rheumatoid arthritis or any other inflammatory arthritis, fibromyalgia, neuropathic pain conditions, bursitis, or acute injury or signs of active infection in the target pain area.
  • Subjects who cannot or will not agree to stop all concomitant analgesic medications, apart from specified protocol supplemental analgesic medications.
  • Subjects with history of seizures within the past 5 years.
  • Subjects who use opioids more than 4 days per week.
  • Pain-condition-specific exclusions:
  • Subjects who received local pain-control procedures, including intra- articular steroid injection in the study knee or intramuscular steroid injection at any site within 6 weeks of entering the study or hyaluronate injection in the study knee within 12 weeks of entering the study.
  • Subjects who have had arthroscopy on either knee or hip within 6 months of entering the study, or open surgery on either knee or hip within 12 months of entering the study.
  • Active-comparator-related exclusions:
  • Subjects who are allergic to or cannot tolerate naproxen or acetaminophen, including history of NSAID-induced asthma, or nasal polyps;
  • Subjects with history of bleeding disorders or history of documented gastrointestinal ulcer disease.

Other protocol specific inclusion/exclusion criteria may apply.

Treatment and study plan

V116517 50-mg tablets

Drug

Taken orally twice daily

V116517 30-mg tablets

Drug

Taken orally twice daily

Naproxen 500-mg capsules

Drug

Taken orally twice daily

Placebo

Drug

Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily

Primary outcomes

  1. Western Ontario and McMaster OA Index (WOMAC) Pain Score

    Time frame: Week 4

Secondary outcomes

  1. WOMAC Physical Function Score

    Time frame: Week 4

  2. WOMAC Stiffness Score

    Time frame: Week 4

  3. Modified Brief Pain Inventory - Short Form (mBPI-SF) Severity of Pain and Interference of Pain

    Time frame: Week 4

  4. Patient Global Impression of Change (PGIC)

    Time frame: Week 4

  5. Supplemental Analgesic Medication Use

    Time frame: Over 4 weeks

Sponsors and collaborators

Lead sponsor

Purdue Pharma LP

Industry

Registry information

Official study title

A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Sep 20, 2012
Registry last updated
Dec 5, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.